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Abstract
The protein kinases are a large family of enzymes that play fundamental roles in propagating signals within the cell. Because
of the high degree of binding site similarity shared among protein kinases, designing drug compounds with high specificity
among the kinases has proven difficult. However, computational approaches to comparing the 3-dimensional geometry and
physicochemical properties of key binding site residue positions have been shown to be informative of inhibitor selectivity.
The Combinatorial Clustering Of Residue Position Subsets (CCORPS) method, introduced here, provides a semi-supervised
learning approach for identifying structural features that are correlated with a given set of annotation labels. Here, CCORPS is
applied to the problem of identifying structural features of the kinase ATP binding site that are informative of inhibitor
binding. CCORPS is demonstrated to make perfect or near-perfect predictions for the binding affinity profile of 8 of the 38
kinase inhibitors studied, while only having overall poor predictive ability for 1 of the 38 compounds. Additionally, CCORPS is
shown to identify shared structural features across phylogenetically diverse groups of kinases that are correlated with
binding affinity for particular inhibitors; such instances of structural similarity among phylogenetically diverse kinases are
also shown to not be rare among kinases. Finally, these function-specific structural features may serve as potential starting
points for the development of highly specific kinase inhibitors.
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Introduction
The protein kinases constitute the largest enzyme family
encoded by the human genome, with currently 518 known
sequences, making up 1.7% of all human genes [1,2]. Because
these protein kinases are intimately involved in cellular commu-
nication and regulation networks, the loss of normal kinase
regulation has been implicated in a wide variety of pathological
conditions. The large number of disease states found to be
associated with kinase dysregulation has motivated the develop-
ment of kinase-specific inhibitor compounds and research to
discover protein kinase inhibitors has come to constitute 20–30%
of the drug development programs at many companies [1].
The bulk of this effort has been directed at identifying inhibitors
that bind at the ATP binding site. However, due to the large number
of existing protein kinase domains and the high degree of (ATP)
binding site similarity among them, designing highly selective
inhibitors has proven difficult. For example, type I kinase inhibitors
that only target the ATP site have typically been found to have low
selectivity across the kinome [3]. To increase inhibitor selectivity,
type II inhibitors bind both the ATP site and the immediately
adjacent allosteric site. By also binding to the allosteric site, type II
inhibitors are able to make additional highly specific interactions,
thereby allowing them to be more selective [3].
Identifying highly specific structural features that can be
uniquely targeted by inhibitors can be facilitated by comparative
analysis of multiple kinase structures [4]. Comparative analysis of
multiple structures allows for the identification of kinase structural
features that are available for inhibitor targeting as well as insight
into the effect of activation conformation dynamics, such as
structural features that are only available for targeting in the
inactive, DFG-out conformation [3–6]. Furthermore, combining
structure and sequence is important when analyzing the kinases
holistically due to the large degree of sequence divergence among
the protein kinases [7]. A specific example of the insight derived
from the comparative analysis of kinase structural features follows.
Many of the effective inhibitor selectivity strategies involve
exploiting the differences in the size of the ATP binding site and
targeting residue variability at a few key positions [3,8]. These
structure-based comparison approaches have proven more useful
than sequence-only measures of overall kinase similarity in
evaluating the potential selectivity profile of inhibitors [8]. For
example, the size of the gatekeeper residue directly moderates the
availability of a hydrophobic pocket. Inhibitors having larger
functional groups that bind this hydrophobic pocket may be able
to select for the roughly 20% of protein kinases that have a
relatively small gatekeeper residue (e.g., Gly, Val, Ala or Thr).
This is because kinases with a larger gatekeeper residue (e.g., Phe)
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do not have a large enough hydrophobic pocket to accommodate
the inhibitor [8]. However, in order to select for an even more
specific subset of the human kinome, it has proven necessary to
take advantage of multiple structural features of the kinase binding
site (both ATP and allosteric sites) simultaneously [3,8].
A review of related work is given below. Recent work has
illustrated that local structural similarity exists among phylogenet-
ically diverse groups of kinases [5,9] and has highlighted the
importance of large-scale, multiple-structure analysis of structure-
affinity relationships among the kinases [9,10].
The PharmMap method [10] incorporates an aligned set of
receptor-ligand co-crystals in order to identify pharmacophores
common to a set of inhibitors. It has been developed to identify
kinase inhibitor pharmacophores useful for selecting molecules for
kinase screening panels.
Huang et al. have utilized a knowledge-based approach to
constructing a minimal binding site ‘‘fingerprint’’ that captures
only a pre-specified set of well-studied, structurally selective
features, such as the size and hydrogen-bonding ability of the
gatekeeper residue [8]. The per-kinase fingerprint utilizes nine
binding site features (e.g., residue type at gatekeeper position) that
have been shown to encode for selectivity among type I inhibitors.
Anecdotally, kinases with similar fingerprints were shown to also
have similar inhibitor selectivity profiles [8], illustrating the utility
of structural features in predicting and understanding kinase
selectivity.
Rather than relying upon pre-specified structural features, the
recently developed Pocketfeature method decomposes a binding
site into all possible ‘‘micro-environments’’ [11]. Pairs of kinase
binding sites with highly similar sets of micro-environments were
anecdotally shown to share a common inhibitor in 9 out of the top
50 most similar (as calculated by PocketFEATURE) kinase binding
site pairs. The CavBase [12] cavity matching approach has been
used to cluster kinase ATP binding cavities from multiple families
across the kinome [5]. The kinase binding cavity clusterings
derived from CavBase have been shown to generally agree with
the sequence-derived kinase families and sub-families [5], demon-
strating that the overall kinase cavity is well-conserved within
families.
Recent work by Jackson et al. demonstrated a related structural
clustering approach to predicting kinase inhibitor binding affinities
[9]. Their geometric hashing approach to whole-site comparison
of the ATP binding pocket was demonstrated to be effective at
identifying possible instances of inhibitor cross-reactivity and
further emphasized the importance of taking into account subtle
conformational changes in the binding site.
However, despite the successes of existing approaches, several
outstanding problems to identifying structural features of the
kinase binding site that are predictive of inhibitor selectivity
remain. The reliance upon a single, representative structure
precludes the ability of existing methods to identify features
common only to active conformations if an inactive structure is
chosen as representative (and vice versa). Additionally, choosing
one representative structure disregards the role that binding site
flexibility and plasticity may play in inhibitor interactions.
Furthermore, the availability of multiple structures for individual
kinases, exhibiting a variety of binding site conformations and
bound ligands, provides a vast quantity of structure data that
remains unexploited by existing approaches. Much of the difficulty
in incorporating multiple conformations per individual kinase
sequence into existing analyses stems from the non-uniform
distribution of available kinase structures, with kinases such as
CDK2 having more than a hundred available crystallographic
structures while other kinases have only a single (or no) available
structure. Finally, the availability of multiple kinase structures
known to bind a given inhibitor and other kinase binding sites
known not to bind that same inhibitor provides a rich set of
structural examples and counter-examples beyond a single
instance of pairwise similarity. Existing receptor-based methods
focus on identifying meaningful pairwise similarity to a character-
ized kinase known to bind a given inhibitor. These methods
currently do not account for the similarity of a given kinase
binding site to other kinase sites that have been characterized to not
bind the inhibitor in question.
To this end we have developed the Combinatorial Clustering
Of Residue Position Subsets (CCORPS) method. CCORPS solves the
following problem: given a set of sequence-aligned kinase
domains (each having §1 available PDB structures) and a per-
sequence inhibitor binding label (either binds, does-not-bind
or unknown), predict whether a given kinase domain binds the
given inhibitor. Taking a set of kinase binding site residue
positions as input, CCORPS identifies clusters of kinases that share
structurally and chemically similar subsets of residue positions.
Given a particular kinase with unknown ability to bind a
particular inhibitor, CCORPS identifies kinase binding sites that
share similar residue positions that are both known to bind and not
to bind the inhibitor (i.e., it finds evidence both for and against
binding a particular inhibitor). Finally, CCORPS aggregates the
residue position subset similarities for all possible k-position
subsets of the kinase binding site and predicts whether or not the
given inhibitor will bind the given uncharacterized kinase binding
site.
In addition to the development of CCORPS, three major results
from the analysis of the human kinome are presented here. First,
the identification of structural features within the kinase ATP
binding site that are correlated with the ability of certain kinases
to bind specific inhibitors is demonstrated. Second, the existence of
affinity-correlated structural features that are shared among
kinases from distinct families of the kinome are enumerated,
shown to be not rare and also to differ depending upon the
inhibitor being analyzed. Third, the ability of CCORPS to predict
the affinity for kinases lacking affinity annotations is quantified and
compared to a recent structural binding site analysis approach [9].
Author Summary
The kinases are a group of essential signaling proteins
within the cell and are the largest family of enzymes
encoded by the human genome. The high degree of
binding site similarity shared across the protein kinases has
made them difficult targets for which to design highly
selective inhibitors, but kinome-wide binding site analysis
can help predict unintended off-target inhibitions. Given
the increasingly large number of available kinase struc-
tures, kinome-wide comparative analysis of binding sites is
now possible. In this paper, the Combinatorial Clustering
Of Residue Position Subsets (CCORPS) method is introduced
and used to synthesize kinome-wide structure datasets
with a kinome-wide inhibitor affinity screening dataset
consisting of 38 kinase inhibitors. CCORPS identifies struc-
tural features of the kinase binding site that are correlated
with an inhibitor binding and uses these features to
predict if this inhibitor will be capable of binding to
uncharacterized kinases. This paper demonstrates the
ability of CCORPS to accurately predict inhibitor binding
and identify features of the kinase binding site that are
unique to kinases capable of binding a given inhibitor.
Clustering of Residues Predicts Kinome Affinity
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CCORPS is demonstrated to make perfect or near-perfect
predictions for the binding ability of 8 of the 38 kinase inhibitors
studied, while only having overall poor predictive ability for 1 of the
38 compounds. The performance of CCORPS for predicting inhibitor
binding is compared to the method of Jackson et al. [9] and shown to
meet or exceed the predictive ability for the subset of the 38
inhibitors also tested by Jackson et al. We also compare CCORPS
against a sequence-based approach and show that they have
complementary strengths. Finally, CCORPS is shown to identify
shared structural features across phylogenetically diverse groups of
kinases that are correlated with binding affinity for particular
inhibitors; such instances of structural similarity among phylogenet-
ically diverse kinases are also shown to not be rare among kinases.
These function-specific structural features may serve as potential
starting points for the development of highly specific kinase inhibitors
and provide a basis for understanding patterns of inhibition by
compounds such as sunitinib that target multiple kinases [13].
In contrast to existing pairwise binding site comparison
approaches, CCORPS provides an automated way to incorporate
the similarity of an uncharacterized binding site to all character-
ized binding site structures, without the need to manually select a
reference binding site. CCORPS also accounts for the similarity of an
uncharacterized binding site to both kinases that bind and those
that do not bind a particular inhibitor.
The high degree of ATP binding site similarity shared across the
protein kinases has made them a difficult target for which to design
highly selective inhibitors. However, by identifying the patterns of
local structural similarity among binding sites at the kinome scale,
potential off-target interactions may be identifiable at earlier stages
of pharmaceutical development and compensated for by further
inhibitor modification. This would allow researchers to make
predictions of binding affinity for a given ligand across the kinome
with less experimental data. Furthermore, the emergence of kinase
inhibitor resistance due to binding site position mutations may be
better understood through the identification of kinases having
similar structural features at the mutated positions. Structural
features that are found to be unique to one or a small number of
chosen kinases may provide the starting point for designing highly
specific inhibitor interactions and therefore highly selective protein
kinase inhibitors.
Methods
The Combinatorial Clustering Of Residue Position Subsets
(CCORPS) method is designed to solve a very general semi-
supervised learning problem:
Find the structural features among the set of proteins that are correlated
with a particular set of annotation labels.
While in the Results section we focus on the specific problem of
predicting ligand binding affinity across the human kinome, we
will first describe CCORPS in its most general form. To solve the
general semi-supervised learning problem stated above, CCORPS
requires the following interface:
Input: an aligned set of protein substructures, where a
substructure is defined as a collection of residues not necessarily
contiguous in sequence but grouped together in 3D.
Input: annotation labels for some of the protein substructures.
Output: predicted annotation labels for the unlabeled protein
substructures.
The per-substructure annotation labels may derived from a
wide range of sources [14–25]. While this paper focuses on the
application of CCORPS for the prediction of inhibitor binding
affinity annotations for the human kinome, CCORPS generalizes to a
variety of annotation prediction problems. The ability of CCORPS to
also identify specificity-determining enzymatic substructures for
the prediction of EC class annotations for 48 different protein
families is outlined in Text S2 and summarized at the end of this
section.
Combinatorial clustering of residue position subsets
In order to identify locally similar features among substructures,
all k-sized combinations of the r residue positions (i.e.,
r
k
 
combinations) are generated. For example, given r~20 and k~3,
all
20
3
 
3-position subsets (1140 subsets) are generated. Then,
each of these position subsets are examined one-by-one. Continu-
ing the example, given the position subset (7,13,14), all the protein
structures are compared by examining the pairwise similarity of
only positions 7, 13, and 14 in isolation (i.e., disregarding the other
17 positions). 3-position subsets are used in this work because they
allow for a unique 3-dimensional lrmsd superposition and are
more computationally tractable than subsets of sizew3, while still
allowing for binding site position decomposition.
The dissimilarity between a pair of substructures is quantified by
a combination of structural distance and chemical feature
dissimilarity introduced in [26]. Specifically, the distance between
any two substructures s1 and s2 is expressed as:
d(s1,s2)~dside chain centroid(s1,s2)zdsize(s1,s2)
zdaliphaticity(s1,s2)zdaromaticity(s1,s2)
zdhydrophobicity(s1,s2)zdhbond acceptor(s1,s2)
zdhbond donor(s1,s2):
The dside chain centroid(s1,s2) term is the pairwise-aligned side chain
centroid lrmsd between the substructures. The remaining terms
account for differences in the amino acid properties between the
substructures s1 and s2 as quantified by the pharmacophore
feature dissimilarity matrix as defined in [26].
For a given set of residue positions, we can calculate a matrix of
pairwise distances between substructures using the distance
measure defined above. Each row can be thought of as a feature
vector that represents how different a protein is with respect to all
other proteins in terms of the selected residues. The distance
matrix is highly redundant. We use Principal Component Analysis
(PCA) to obtain a low-dimensional embedding. Our previous work
[27] showed that this dimensionality reduction typically results in
negligible information loss. Some technical details on how we
correct for overrepresentation are described in Text S3. The
dimensionality-reduced feature vectors are then clustered to
identify sub-groups that share strong structural similarity. The
number of clusters is not known beforehand and the number of
clusters will vary depending on the set of positions being
compared. The Gaussian Mixture Model (GMM) clustering method
implemented in the mclust package [28] was used to identify both
the number of clusters present and the cluster memberships for
each of the feature vectors.
Selecting Highly-Predictive Clusters (HPCs)
The above feature vector computation and clustering steps are
repeated for each possible 3-position subset in order to compare all
possible local structural features across all proteins. Structural
variation in most subsets is not expected to be informative, either
Clustering of Residues Predicts Kinome Affinity
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because no significant variation is present, or because spurious
patterns can occur due to chance. However, functionally relevant
structural variation can be detected with many different subsets
and therefore distinguished from random patterns, as will be
shown below.
A cluster that is dominated by one annotation label can be used
to predict the label for other structures in that cluster whose
annotation is unknown. We therefore call such clusters ‘‘highly
predictive’’ (HPCS). Identification of HPCs is performed by
selecting a minimum threshold for the label purity of clusters,
and then selecting all clusters with equal or greater label purity
than this minimum as HPCS; we used the strictest purity threshold
possible (1.0 or 100% purity) in this work (see Fig. 1). In general,
purity is calculated for a multiset of labels, L, as
purity~IL(mode(L))=DLD where IL is the multiplicity function of
a label within the multiset L and mode(L) is the most frequent
label within L. As with the dimensionality reduction mentioned
above, we need to correct for overrepresentation bias, the details of
which are described in Text S3. Purity alone does not account for
the distinctness of the proteins in the cluster relative to the
remainder of the dataset. For example, an hpc for label l1 that
partially overlaps a second hpc for label l2 is less likely to be
informative than an l1 cluster greatly separated from the
remainder of the dataset. The ‘‘degree of separation’’ or
‘‘distinctness’’ of a cluster was quantified by calculating the cluster
silhouette score [29]. The mean silhouette score for a cluster was
then used as a further selection criteria for identifying HPCS by
removing potential HPCS with negative average silhouette scores
(malformed clusters).
Support Vector Machine-based (SVM) decision boundary
Each time an unlabeled protein falls within an HPC, that protein
receives a single vote in favor of the majority label associated with
the HPC. Because a protein can be a member of at most one cluster
per k-position subset, the maximum number of votes any protein
can receive is equal to the number of possible k-position subsets.
For any given k-position subset, it is possible that all clusters are
HPCS or that no clusters are HPCS, depending on how the labels
are distributed among the clusters. It is also possible that a protein
may never fall within any hpc and therefore would receive zero
votes for any label; such proteins are excluded from further
analysis after the voting step. In the experiments described below
this case rarely occurred. After tallying the label votes across all k-
position subsets, the label predicted for a given structure is
determined by an SVM-derived decision boundary as described
below.
Given a set of label votes that have been determined for an
unlabeled structure, the threshold(s) used to decide which of the
two or more label classes to assign to the structure requires the
definition of a decision boundary procedure. For example, given a
set of annotation labels containing the label classes ftrue,falseg
(e.g., indicating whether a kinase is known to bind to a given
ligand), a simple decision rule may be that given a structure with
w1 true vote, predict the true label for that structure. However,
determining a single threshold for deciding the number of label
votes required to classify a structure into one of several classes is
difficult to generalize.
Because CCORPS is a semi-supervised approach, the labels for the
training structures are known and can be used to empirically
estimate a vote count decision boundary. For example, given
structure X with known label, the number of times that X
appeared in a false HPC or a true HPC, across all k-position
subsets, can be calculated using the same approach as for
unlabeled structures. The structure X is then represented by an
DlD-dimensional vote vector, where each of the l dimensions
corresponds to the number of votes X received for label li,1ƒiƒl
(l~2 for the case of kinase binding affinity, since we only have
false and true labels). Application of this procedure to all labeled
structures in the dataset provides an empirical basis for calculating
a decision boundary in the vote space given the vote distribution
for labeled structures. For example, the blue and red points shown
in the scatter plot of Fig. 2 denote the vote vectors for training set
substructures with known true and false labels, respectively.
Given the vote vectors calculated for all labeled training set
substructures in the dataset, it is then possible to train any number
of classifiers in order to determine a decision boundary. To
compute a decision boundary in the vote space for classifying
unlabeled proteins, SVMs were selected in this paper. First, an SVM
(linear kernel) is trained using the vote vectors of labeled training
set substructures. For example, the decision boundary determined
Figure 1. Illustration of cluster evaluation procedure. The star
and diamond symbols represent structures with known labels and the
question marks represent structures with an unknown label. Clusters A
and B will both be selected as HPCS for their respective labels (star and
diamond, respectively) because they are each pure in a single label
(unknown labels are disregarded). Cluster C will not be selected as an
HPC because it has low purity.
doi:10.1371/journal.pcbi.1003087.g001
Figure 2. Decision boundary for label vote vectors computed
by SVM. In the above scatter plot, each point corresponds to the
number of true/false votes accumulated by each substructure across all
clusterings. Combining the above label vote vectors with the known
labels for substructures to train an SVM (using linear kernel) results in the
decision boundary shown as the bold black line. The red and blue
regions (right and left sides of the boundary, respectively) denote the
values for which the predicted label will be false and true, respectively.
Blue points indicate substructures known to have the true label while
red points denote the false label. In the case of Roscovitine above,
wide separation between the two classes exists.
doi:10.1371/journal.pcbi.1003087.g002
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by training an SVM on vote vectors is shown in Fig. 2 as the bold,
black line. Next, for an unlabeled substructure with a given vote
vector, the label for the substructure can be predicted by
determining which side of the SVM decision hyperplane the
unlabeled structure falls within. As illustrated in Fig. 2, test vote
vectors falling within the blue region will be predicted as having
the true label and those falling within the red region, the false
label. For training SVMs and calculating the p-values of predictions
made by those SVMs, libSVM [30] was used in this work.
Validation experiments and method generalization
To validate the predictive ability of the structural features
identified by CCORPS an extensive dataset of 48 families was
automatically constructed using the Pfam database [17] as a
source of well-curated protein alignments. The annotation labels
analyzed in the validation set were per-structure Enzyme
Commission (EC) number classifications. Cross-validation was
performed in order to evaluate the predictive power of CCORPS and
the utility of the distinguishing structural features identified. The
overall classification accuracy of CCORPS (Text S2) when applied to
the validation dataset demonstrates the ability of CCORPS to identify
structural features that distinguish functionally different protein
homologs and the ability of CCORPS to generalize to non-kinase
protein families.
Results
First, we will introduce the components of the kinome structure
and affinity datasets used in this work. Next, structural features of
the kinase binding site that are identified by CCORPS to be
predictive of inhibitor binding ability are presented. Then, cases of
these predictive structural features that are common to phyloge-
netically diverse sets of kinases are highlighted. Finally, the
performance of CCORPS for predicting the binding ability of
inhibitors across the kinome is quantified and compared to the
related approach of Jackson et al. [9] as well as a sequence-based
approach.
Dataset
In order to enable the kinome-scale analysis of the protein
kinase ATP binding site presented here, a dataset of protein kinase
binding site structures was assembled and then mapped to the
affinity dataset of Karaman et al. [31]. Karaman et al. studied the
affinity of 38 kinase inhibitors across 317 kinases and was one of
the most comprehensive studies of kinase inhibitor selectivity at
that time. Mapping a structure-affinity-phylogeny dataset by
further incorporating the kinome family labeling of Manning et al.
[2] has enabled the incorporation of all available crystallographic
structures of the ATP binding site and the analysis of shared
structural features between major kinase families that is presented
later in this paper.
Kinase structure dataset. The kinome structural dataset
was constructed from all structures (domains) annotated as
belonging to PFAM:Pkinase and PFAM:Pkinase_Tyr (all e pk
domains, apks excluded) in release 25 of PFAM (2154 total
domains before filtering). After the binding site residue positions
to analyze were selected, as detailed in the following section, and
proteins having one or more gaps at those positions were
excluded, a total of 1958 structures remained. These 1958
structures correspond to 208 unique kinase proteins. The
distribution of sequences and structures across the seven major
kinome families is shown in Table 1. Of the 1958 kinase
structures within the dataset, 1281 (65.4%) were part of the
kinome inhibitor affinity dataset of Karaman et al. [31] and
therefore have known annotation labels for each of the 38
inhibitors that were experimentally determined by Karaman et
al. [31]. The dataset contained a large number of active DFG-in,
inactive DFG-out and other conformations.
Binding site position selection. All residues having one or
more atoms within 5 A˚ of one or more imatinib atoms from the
imatinib-bound structures PDB:2pl0 or PDB:3hec were selected as
candidate binding site positions. Candidate positions were
eliminated if they corresponded to highly gapped columns in
either the PFAM:Pkinase or PFAM:Pkinase_Tyr Multiple Sequence
Alignments (MSAS). After filtering, 27 binding site residue positions
remain (shown in Fig. 3): 30, 38, 51–53, 71, 74, 75, 78, 83, 84,
104–109, 111, 146–149, 157, 166–169 (residue numbering
according to PDB:3HEC). Imatinib was chosen as a reference
inhibitor for selecting the binding site positions to include in the
analysis because it is of the large type II kinase inhibitor variety
and extends both into the ATP binding pocket as well as the
neighboring allosteric pocket. The cutoff distance of 5 A˚ was
selected in order to be consistent with the binding site selection
cutoff chosen by Jackson et al. [9]. For full details on the mapping
and alignment of positions among structures within the kinase
dataset please refer to Text S1.
Kinase inhibitor affinity dataset. The affinity (Kd) for 38
small molecule kinase inhibitor compounds was determined for a
set of 317 kinases using an in vitro competition binding assay by
Karaman et al. [31]. The 38 inhibitors tested include staur-
osporine, 1 lipid kinase inhibitor, 15 serine-threonine kinase
inhibitors and 21 tyrosine kinase inhibitors. Affinity values were
mapped from the Karaman et al. [31] dataset to the kinome
structural dataset by mapping the NCBI RefSeq IDs provided by
Karaman et al. [31] to the UniProtKB IDs [32] of the proteins in
the structural dataset. 137 of the 208 protein sequences in the
structural dataset mapped to the affinity dataset published by
Karaman et al. [31].
In order to simplify the problem of correlating structural
features with binding affinities, the binding affinity (Kd) values
were binned into 2 classes (true/false) by thresholding the
affinity values at 10 mM (i.e.,v10 mM?true;§10 mM?false).
This 10 mM cutoff between the two label classes was used
consistently across all inhibitors and selected because it is the
largest Kd considered by Karaman et al. [31] to be meaningful for
inhibitor binding in the screening dataset used in their work [31].
Table 1. Statistics for the human kinome dataset.
Kinase Family AGC CAMK CK1 CMGC Other STE TK TKL Unclassified
# Structures 171 231 20 500 114 55 445 58 364
# Sequences 19 34 6 33 18 17 47 9 75
# Annotated 6 13 2 16 5 11 35 6 43
doi:10.1371/journal.pcbi.1003087.t001
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Interpretation of Highly Predictive Clusters (HPCs)
The process by which CCORPS recognizes structural features that
are associated with kinase binding affinity is through the
identification of Highly Predictive Clusters (HPCS). Given the
27-position binding site (Fig. 3), CCORPS computes a clustering for
each of the
27
3
 
~2925 unique 3-position subsets. For example,
consider the 3-residue substructure shown in Fig. 4A. The 3
residues shown correspond to 3 positions in the full kinome
alignment and the corresponding residues for each structure in the
kinome dataset are structurally compared to compute the
substructure clustering shown in Fig. 4B. Each of the 1958
substructures within the kinase structure dataset is shown in Fig. 4B
as a single point. The color of each point in Fig. 4B corresponds to
the cluster assignment as computed by CCORPS.
Several informative observations regarding kinase structural
diversity and its association to inhibitor binding affinity can be
made by further examination of the substructure clustering shown
in Fig. 4B. Immediately upon examination of the substructure
clustering it can be noted that multiple distinct clusters of kinases
exist. This observation alone indicates that the 3-position
substructure that resulted in this clustering is highly diverse
among kinase binding sites. Conversely, the presence of a single
large cluster would indicate that the 3-position substructure was
structurally conserved, exhibiting little variance across the kinome;
indeed instances of clusterings with a single dominating cluster
were also observed for some 3-position subsets. As demonstrated in
Fig. 4C, where one randomly selected representative substructure
is shown for each of the 21 clusters identified by CCORPS, both the
geometry and residue types vary significantly for this 3-position
subset.
By incorporating the affinity annotation labels for a particular
inhibitor, further observations can be made about the association
between the 3-position substructure shown in Fig. 4A and the
kinases capable of binding that inhibitor. For example, mapping
the affinity annotation labels for the inhibitor flavopiridol onto the
substructure clustering (Fig. 4D) reveals that some of the clusters
consist of only a single annotation label while others are a mixture
of labels. In Fig. 4D, kinases capable of binding flavopiridol are
colored red (true label), kinases incapable of binding flavopiridol
are colored black (false label) and kinases lacking affinity
annotation are colored white (undefined label). As shown in
Fig. 4D, multiple clusters of purely true labels exist and are
considered to be HPCS by CCORPS.
The existence of true-only clusters indicates that the 3-positions
shown in Fig. 4A are a distinguishing structural feature for
identifying kinases that bind flavopiridol. More interestingly,
however, is the fact that multiple, structurally distinct versions of
the same 3-position substructure exist for different kinases that all
are capable of binding flavopiridol. This result is significant because
it indicates that across the kinome there are different structural
motifs that are associated with binding flavopiridol, as opposed to a
single, shared structural motif across all flavopiridol-binding kinases.
The ability to identify multiple structural motifs that can each be
associated with inhibitor binding is a strength of CCORPS.
Furthermore, the existence of clusters containing only kinases
incapable of binding flavopiridol can also be observed in Fig. 4D.
These HPCS are also informative because they identify particular
structural versions of the 3-position substructure in Fig. 4A that are
all incapable of binding flavopiridol. Finally, clusters consisting of
a mixture of kinases that are both capable and incapable of
binding flavopiridol can be identified in Fig. 4D. For kinases in
these clusters, the 3-position substructure is not a distinguishing
feature of flavopiridol-binding ability.
Finally, while flavopiridol is discussed in detail here for
illustration, the same analysis was computed by CCORPS for each
of the 38 different inhibitors within the affinity dataset. For each of
the inhibitors, the affinity labels can be mapped separately onto
the same substructure clustering as shown in Fig. 5. However, it
should be noted that no information is shared between the results
for different inhibitors in this work; that is, each inhibitor is
computed in a fully separate CCORPS computation (the substructure
clusterings do not vary, just the annotation labels).
Examination of the affinity-annotated substructure clusterings
shown in Fig. 5 reveals that the set of clusters which are HPCS
varies greatly depending on the inhibitor considered. While the
flavopiridol-annotated substructure clustering contains multiple
HPCS for both true and false labels, the correspondingly
annotated clustering for other inhibitors, such as VX-745, PI-103
and imatinib, contain only false HPCS. This result demonstrates
that the substructures that are informative of inhibitor binding are
inherently inhibitor-specific. That is, a subset of binding site
positions that are predictive for one inhibitor are not necessarily
predictive for another inhibitor.
It is important to note that Fig. 4 and Fig. 5 represent the same
clustering for just one 3-residue substructure. However, all 2925
clusterings are computed and all HPCS detected in these
clusterings are used to predict binding affinity. The particular
three-residue subset shown in Fig. 4A was chosen because the
resulting clustering exhibits a number of illustrative features. First,
the clustering is relative ‘‘clean’’ with well-separated clusters.
Second, it contains highly predictive clusters for both binding and
not binding to flavopiridol (the ocher cluster in the top-left and the
Figure 3. Kinase binding site definition: The 27 alignable residue
positions (blue) within 5 A˚ of the bound imatinib molecule (yellow) are
mapped on to protein kinase structure PDB:3HEC.
doi:10.1371/journal.pcbi.1003087.g003
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red cluster in the bottom right of figure Fig. 4B, respectively).
None of these features are essential for predicting binding affinity;
all automatically selected HPCS in all clusterings are used to
predict affinity, each casting one ‘‘vote.’’
Phylogenetically diverse HPCs
Numerous instances of cross-family affinity for both type I and
II kinase inhibitors have been identified, as was clearly illustrated
by the kinome affinity maps created by Karaman et al. [31]. It is
important to identify structural features shared among phyloge-
netically diverse kinases that share affinity for a particular
inhibitor, because they provide a basis for reasoning about
inhibitor cross-reactivity when overall sequence similarity will be
low. Furthermore, by identifying these shared structural features, it
may be possible to rationally re-engineer the specificity of
inhibitors by avoiding the targeting of these features, since they
are not unique to the intended kinase target. In order to identify
the number of instances of cross-family structural features that can
Figure 4. Highly predictive clusters. (A) Structure of lck (PDB:2pl0) with a 3-position substructure shown in blue stick representation (Thr-316,
Tyr-318, Gly-322) and bound imatinib molecule in red. (B) Substructure embedding computed by CCORPS when comparing the 3-positions shown in A
across the entire 1958 structure dataset. Each point in the clustering represents a single 3-residue substructure. The coloring indicates the cluster
membership of each substructure (21 clusters in total are shown). (C) Aligned 3-residue substructure representatives, from each of the 21 clusters
identified by CCORPS, for the 3-position subset shown in A. The color of each substructure corresponds to its cluster assignment. (D) Same embedding
as in B, but now colored according to affinity. The red and black coloring of each point indicates true and false affinity labels for flavopiridol,
respectively, while white indicates substructures lacking affinity annotations.
doi:10.1371/journal.pcbi.1003087.g004
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Figure 5. Affinity annotation labeling for all 38 inhibitors. The substructure clustering computed for the same 3 positions examined in Fig. 4
is relabeled above for each of the 38 inhibitors included in the dataset. In each cell above, red and black indicate the true and false affinity labels,
respectively, for each inhibitor, while white indicates a lack of annotation. As can be noted by comparing the distribution of red points across the
different inhibitors, for most inhibitors, the kinase proteins capable of binding to them are not distributed in a single cluster, indicating structurally
diverse features exist among the kinases selected by each inhibitor.
doi:10.1371/journal.pcbi.1003087.g005
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be associated with specific inhibitor binding, the distribution of
substructure clusters across all 3-position subsets was analyzed.
Each individual cluster, across all 2925 clusterings and all 38
inhibitors, was evaluated to calculate the purity of both affinity
labels and family-level phylogenetic labels. For example, a cluster
containing 3 distinct kinase sequences with affinity labels
ftrue,false,trueg and family labels {AGC, CAMK, TK} would have
an affinity purity of 0:66 and a phylogenetic purity of 0.33. By
plotting the affinity and phylogenetic purity scores of each cluster
(separately for each inhibitor) as shown in Fig. 6, the distribution of
clusters across the spectrum of possible scores can be evaluated.
Note that only the clusters having a true label majority are plotted
in Fig. 7 (i.e., a true label majority is§0:5 purity in the true label).
Additionally, Table 2 lists per inhibitor statistics for cluster
distributions shown in Fig. 7.
In order to build intuition for interpreting the cluster
distributions, the cluster distribution for VX-680 (Fig. 7) is
examined in more detail because it is representative of the
distribution for many of the other inhibitors. As listed in Table 2,
23,495 clusters were identified by CCORPS that have§0:5 purity in
the true label for VX-680 (hereafter referred to as true-majority
clusters). Only these true-majority clusters are plotted in the
cluster distribution shown in Fig. 7, meaning the minimum
‘‘affinity purity’’ displayed in Fig. 7 is 0.5 by definition (because
only 2 different affinity labels exist, true and false).
As can be seen in Fig. 7, the vast majority of clusters identified
by CCORPS have low affinity purity as well as low phylogenetic
purity. This is to be expected because highly conserved portions of
the kinase ATP binding site are known to exist. Structural features
that consist of conserved residue positions will be common to
many kinases from different families due to the fact that these
positions are so heavily conserved, which explains the low
phylogenetic purity of these clusters. Furthermore, these conserved
features are unlikely to be correlated with the affinity for a
particular inhibitor because most inhibitors have been engineered
to not have broad cross-reactivity across the kinome. Staurospor-
ine is an exception as it is a very non-selective inhibitor due to its
interaction with highly conserved binding site features; the cluster
distribution corresponding to staurosporine (Fig. 6) is markedly
different from the other inhibitors with most clusters having high
affinity purity across a range of phylogenetic purity values.
Examination of the extremes of the VX-680 cluster distribution
reveals further insights into the frequency of structural similar
features among kinases with different degrees of sequence
similarity. Clusters having a phylogenetic purity of 1.0 (i.e., all
proteins belong to the same family) but having low affinity purity
exist, and for VX-680 276 such clusters were identified by CCORPS.
This observation is interesting because it illustrates that kinases
sharing sequence similarity (relative to kinases outside the family)
have multiple common structural features that are not informative
of the ability of these kinases to bind VX-680 and are therefore
unlikely to be good features to target in design studies. Because
CCORPS only incorporates clusters with high affinity purity (i.e.,
HPCS), these conserved structural features that are not indicative
of VX-680 binding are ignored by CCORPS when predicting affinity
for unannotated kinases. This observation can also be made for
each of the other inhibitors as shown in Fig. 6.
Another interesting extreme of the VX-680 cluster distribution
to examine is the existence of HPCS that are phylogenetically
diverse. The HPCS selected by CCORPS correspond to the right-
most column of points in Fig. 7; these clusters all have an affinity
purity of 1.0 for VX-680 and therefore contain only structures with
known VX-680 affinity. As can be noted in Fig. 7, HPCS exist at a
range of phylogenetic purity values. CCORPS identified a total of
2707 HPCS for VX-680, and 1786 (66%) of these HPCS contain
proteins belonging to two or more distinct kinase families. This
result demonstrates that CCORPS is capable of identifying cross-
family structural features that are associated with VX-680 binding.
Furthermore, this result is not unique to VX-680. As shown in
Fig. 6 and tabulated in Table 2, cross-family structural features
associated with inhibitor binding were identified for all of the
inhibitors tested with the exception of GW-2580, for which no
true-majority clusters were identified.
Examination of the cluster distributions across each of the
inhibitors reveals a wide range of observations. While many
inhibitors have a cluster distribution similar to that of VX-680, for
some inhibitors CCORPS identified relatively fewer true-majority
clusters. For example, only 133 clusters with affinity purity w0.5
were identified by CCORPS for SB-431542 and all of these happen
to be HPCS. However, even among this relatively low number of
HPCS, 69 (52%) of the clusters contain kinases from two or more
families. As demonstrated by the corresponding distributions for
all 38 inhibitors in Fig. 6, such shared structural similarity is not
rare.
Predicting kinase-inhibitor binding
The approach used by CCORPS to classify an unlabeled kinase is
to identify the cluster to which the unlabeled kinase belongs. If the
associated cluster is an hpc, the label for the hpc is transferred to
the unlabeled kinase. Non-informative clusters containing a mix of
labels (non-HPCS) do not contribute to the label prediction
process. This ‘‘co-clustering’’ analysis approach is repeated for all
of the 2925 substructure clusterings and the final label prediction
for an unlabeled kinase is then selected as detailed in Methods.
The ability of CCORPS to predict the binding of each inhibitor for
proteins within the annotated structural dataset was assessed using
the cross-fold validation approach described in the following
section. For each of the 38 inhibitor annotation label sets, an
independent evaluation of CCORPS was performed. No information
was shared among the evaluations in order to validate the
predictive ability of CCORPS to identify structural features predictive
of the binding ability of each inhibitor independently.
Cross-fold validation. To assess the utility of HPCS for
identifying substructure positions indicative of functional special-
ization, cross-fold validation was performed for each family within
our dataset. The structures within a protein family were first
divided into 70% sequence identity groups (NR-clusters) so that no
protein in a test set shares w70% sequence identity with any
protein in the training set. The sequence identity is computed over
the domain (i.e., not the whole sequence nor just the binding site).
Because of the non-uniform distribution of structures across the
NR-clusters, the number of structures in the test set varies with each
fold. In each fold, structures that were part of the test set are
marked with label unknown, and are disregarded when calculating
the purity of clusters (defined in Methods) during the HPC selection
step, just as the structures with truly unknown label. Finally,
standard k-fold cross validation was performed with each of the
NR-clusters each being one fold (i.e., k~DNR-clustersD). Given the
NR-clusters-based fold partitioning above, the training set is used to
identify HPCS and train an SVM-based classifier to predict labels
for kinases in the test set.
Prediction performance. For each of the 38 inhibitors
included in the affinity dataset, CCORPS was used to predict the set
of kinases able to bind to that inhibitor. The performance of
CCORPS was assessed for each inhibitor, independently, by
computing the Receiver Operator Characteristic (ROC) curve for
the set of predictions, which evaluates the sensitivity (# true
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Figure 6. Distribution of phylogenetic and affinity purity cluster scores for all 38 inhibitors. As can be seen in the case of drugs such as
imatinib and lapatinib, very few clusters that have a majority of true labels were identified, yet clusters of phylogenetically diverse structures all
having true labels can be identified. Staurosporine exhibits a reflected distribution relative to the other drugs, because due the nature of its non-
selectivity across the kinome, instances of phylogenetically distant structures that exhibit Staurosporine affinity are common. Refer to Fig. 7 for
additional details.
doi:10.1371/journal.pcbi.1003087.g006
Clustering of Residues Predicts Kinome Affinity
PLOS Computational Biology | www.ploscompbiol.org 10 June 2013 | Volume 9 | Issue 6 | e1003087
positives/(# true positives + # false negatives)) at each specificity
(# true negatives/(# true negatives +# false positives)) value. The
ROC curves for the predictor constructed by CCORPS are shown in
Fig. 8 for each inhibitor and the Area Under Curve (AUC) for each
roc curve is listed in Table 3. Additionally, the Precision-Recall
(PR) curve for each inhibitor can be found in Fig. 9. The PR curve
plots the precision (# true positives/(# true positives + # false
positives)) versus the recall (equivalent to sensitivity).
In order to make a direct comparison of the performance of
CCORPS to the work of Jackson et al. [9], another performance
measure, the enrichment factor, was also computed per inhibitor
tested. The enrichment factor of the top 5% most highly ranked
true affinity predictions (for a given inhibitor) can be calculated as
follows:
E5%~
Atop 5%=Ntop 5%
Atotal=Ntotal
,
where Atop 5% is the number of structures with known affinity for a
given inhibitor (# actives) in the top 5% of most confident
predictions ranked by p-value as computed by CCORPS, Ntop 5% is
the total number of structures in the top 5%, Atotal is the total
number of active structures in the dataset and Ntotal is total
number of structures in the dataset. The enrichment factor at 5%
(E5%) for each inhibitor is shown in Table 3 and where available,
the corresponding E5% values from Jackson et al. [9] are listed
alongside. It should be noted that the E5% values are not directly
comparable between CCORPS and Jackson et al. [9] as listed in
Figure 7. Distribution of phylogenetic and affinity purity
cluster scores for VX-680. Each point in the scatter plot above
marks the purity for the drug affinity true label on the x-axis and the
phylogenetic label purity on the y-axis. For example, a point above
located at the coordinates (1:0,0:2) denotes a cluster that is 100% pure
in the true drug affinity label (for VX-680 in this case) but is only 20%
pure in the most common phylogenetic label present; that is, this
cluster indicates one instance of structural similarity among phyloge-
netically diverse proteins that also coincides with having affinity for VX-
680. Conversely, a point at the coordinates (0:5,1:0) indicates a cluster
that contains only structures from one phylogenetic (family-level)
branch but contains an equal proportion of true and false affinity
labels; that is, a case where structurally similar, closely related
(phylogenetically) structures have different affinities for VX-680. Each
point is semi-transparent so that darker areas in the plot indicate a
higher density of points.
doi:10.1371/journal.pcbi.1003087.g007
Table 2. Phylogenetically diverse HPC statistics per inhibitor.
Inhibitor # true -HPCS # §2 Families
ABT-869 345 249
AMG-706 274 202
AST-487 2415 1955
AZD-1152HQPA 506 374
BIRB-796 893 730
BMS-387032 728 447
CHIR-258 1577 800
CHIR-265 242 184
CI-1033 1247 704
CP-690550 11 5
CP-724714 115 89
Dasatinib 1848 1193
EKB-569 1133 684
Erlotinib 596 456
Flavopiridol 921 481
GW-2580 0 0
GW-786034 1443 809
Gefitinib 203 169
Imatinib 57 45
JNJ-7706621 4087 2761
LY-333531 634 314
Lapatinib 115 89
MLN-518 92 70
MLN-8054 435 301
PI-103 182 69
PKC-412 3419 2368
PTK-787 7 6
Roscovitine 593 335
SB-202190 644 513
SB-203580 738 546
SB-431542 133 69
SU-14813 4415 3116
Sorafenib 561 405
Staurosporine 17098 14802
Sunitinib 5525 4077
VX-680 2707 1786
VX-745 189 151
ZD-6474 1059 610
For each inhibitor, the total number of true -HPCS (column ‘‘# true -HPCS’’) is
shown. The subset of true -HPCS that consist of proteins from two or more of
the kinase families defined by Manning et al. [2] (column ‘‘# §2 families’’) are
also shown. The multitude of true -HPCS that include proteins from distinct
families of the kinome can be noted by the relatively large percentage (73%
overall across all inhibitors) of HPCS that span families. All of these 41964
instances of structurally similar features between families are provided in
Dataset S1.
doi:10.1371/journal.pcbi.1003087.t002
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Table 3, due to the fact that the maximum possible enrichment
(Emax) for a given inhibitor is dataset-dependent, and the dataset
presented in this work is larger both in number of structures
compared and the number of per-inhibitor affinity annotations.
The ratio of E5% to Emax is a slightly better basis for comparison,
since it normalizes for differences in Emax.
Figure 8. Per inhibitor Receiver Operator Characteristic (ROC) curves. The x- and y-axis plot (1-specificity) and sensitivity, respectively, both
ranging from 0 to 1. The Area Under Curve (AUCROC) as well as the E5% per drug can be found in Table 3. As shown above, CCORPS is able to construct
a near-perfect classifier for several drugs, such as PI-103, SB-431542. The classifiers constructed for some inhibitors, such as flavopiridol, are able to
achieve high precision, but only at low sensitivities (recalls), as further illustrated by the pr curves in Fig. 9.
doi:10.1371/journal.pcbi.1003087.g008
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As shown in Table 3, CCORPS achieves high predictive
performance across the 38 inhibitors tested. As quantified by
ROC AUC w0:90, CCORPS achieved perfect or near-perfect
predictive ability for 8 of the 38 inhibitors: AMG-706, CHIR-
265, CP-690550, CP-724714, Lapatinib, PTK-787, Roscovitine
and SB-431542. Furthermore, CCORPS is demonstrated to be very
competitive with the method by Jackson et al. [9] as also shown
in Table 3. In the case of Lapatinib, CCORPS significantly
improved on Jackson et al. [9]. Comparison of enrichment scores
ignores another important difference: with our method no
Table 3. Affinity prediction performance of CCORPS for the kinase inhibitors.
CCORPS Jackson et al. [9] Sequence-based
Inhibitor AUCROC AUCPR E5%/Emax E5%/Emax AUCROC AUCPR E5%/Emax
ABT-869 0.50 0.23 0.51 (4.27/8.41) 0.64 0.36 0.59 (5.00/8.43)
AMG-706 0.96 0.74 0.87 (5.91/6.77) 0.77 0.56 0.84 (5.66/6.71)
AST-487 0.81 0.86 1.00 (1.71/1.71) 0.84 0.90 1.00 (1.71/1.71)
AZD-1152HQPA 0.65 0.27 0.46 (3.12/6.77) 0.69 0.34 0.45 (3.07/6.78)
BIRB-796 0.75 0.48 0.51 (1.67/3.28) 0.91 (3.65/3.98) 0.54 0.33 0.16 (0.51/3.27)
BMS-387032 0.88 0.80 1.00 (3.69/3.69) 0.93 0.88 1.00 (3.69/3.69)
CHIR-258 0.86 0.81 1.00 (4.05/4.05) 0.93 0.85 1.00 (4.05/4.05)
CHIR-265 0.97 0.81 0.90 (6.61/7.31) 0.91 0.71 0.67 (4.86/7.24)
CI-1033 0.70 0.42 0.56 (2.48/4.47) 0.77 0.57 0.94 (4.20/4.48)
CP-690550 0.94 0.22 0.25 (8.33/32.79) 0.35 0.03 0.05 (1.54/32.85)
CP-724714 1.00 0.99 0.86 (20.30/23.69) 0.71 0.07 0.00 (0.00/23.72)
Dasatinib 0.70 0.48 0.27 (0.78/2.90) 0.74 0.67 0.94 (2.71/2.89)
EKB-569 0.79 0.56 0.71 (3.31/4.63) 0.82 0.60 0.83 (3.84/4.64)
Erlotinib 0.67 0.38 0.51 (2.79/5.49) 0.75 (6.89/9.19) 0.74 0.46 0.94 (5.15/5.50)
Flavopiridol 0.71 0.68 1.00 (3.09/3.09) 0.87 0.86 1.00 (3.09/3.09)
GW-2580 0.87 0.01 0.00 (0.00/255.80) 0.30 0.00 0.00 (0.00/256.20)
GW-786034 0.70 0.58 0.94 (5.14/5.49) 0.75 0.53 0.84 (4.60/5.45)
Gefitinib 0.65 0.29 0.37 (3.38/9.27) 0.55 0.11 0.00 (0.00/9.28)
Imatinib 0.63 0.21 0.38 (4.51/11.84) 0.25,0.50 (2.99,5.98/11.95) 0.63 0.22 0.55 (6.49/11.86)
JNJ-7706621 0.81 0.75 0.59 (1.17/2.00) 0.85 0.87 1.00 (2.00/2.00)
LY-333531 0.85 0.55 0.65 (4.57/7.03) 0.90 0.55 0.80 (5.61/7.04)
Lapatinib 1.00 0.99 0.86 (20.30/23.69) 0.00 (0.00/19.92) 0.71 0.07 0.00 (0.00/23.72)
MLN-518 0.87 0.24 0.16 (3.44/21.68) 0.75 0.28 0.20 (4.41/21.71)
MLN-8054 0.72 0.57 0.73 (4.99/6.84) 0.79 0.60 0.97 (6.64/6.85)
PI-103 0.75 0.11 0.00 (0.00/16.40) 0.93 0.30 0.30 (4.75/16.01)
PKC-412 0.49 0.40 0.00 (0.00/2.20) 0.81 0.71 0.53 (1.17/2.20)
PTK-787 0.95 0.22 0.22 (7.68/34.57) 1.00 0.99 0.58 (20.02/34.62)
Roscovitine 0.92 0.78 0.97 (4.66/4.81) 1.00 (2.81/2.81) 1.00 1.00 1.00 (4.82/4.82)
SB-202190 0.88 0.71 0.92 (3.90/4.24) 0.91 0.79 0.97 (4.08/4.21)
SB-203580 0.78 0.54 0.60 (2.24/3.71) 1.00 (5.43/5.43) 0.84 0.68 0.87 (3.23/3.69)
SB-431542 1.00 0.98 0.41 (20.30/49.19) 0.44 0.02 0.00 (0.00/49.27)
SU-14813 0.68 0.43 0.27 (0.83/3.08) 0.87 0.78 1.00 (3.09/3.09)
Sorafenib 0.82 0.62 0.87 (3.58/4.10) 0.63 0.48 0.89 (3.63/4.08)
Staurosporine 0.83 0.96 0.97 (1.11/1.14) 0.93 0.99 1.00 (1.15/1.15)
Sunitinib 0.70 0.48 0.21 (0.52/2.51) 0.87 0.83 1.00 (2.52/2.52)
VX-680 0.77 0.63 0.56 (1.64/2.95) 0.79 0.68 0.94 (2.77/2.95)
VX-745 0.87 0.47 0.48 (3.02/6.33) 0.49 0.19 0.36 (2.28/6.34)
ZD-6474 0.90 0.77 0.95 (4.30/4.52) 0.90 0.81 1.00 (4.53/4.53)
mean 0.80 0.55 0.59 0.76 0.54 0.66
For each of the 38 inhibitors in the affinity dataset of Karaman et al. [31], the prediction performance of CCORPS, the Jackson et al. [9] method, and the sequence-based
method is shown below. The performance of the Jackson et al. [9] method is shown alongside that of CCORPS for the subset of inhibitors tested by both methods. Note
that for imatinib, two E5% values are provided by Jackson et al. [9] because each value is derived by selecting a different reference structure. While the mean auc values
and enrichment scores are close, the standard deviations of the differences between the corresponding columns (0.21, 0.33, and 0.36, respectively) highlight that the
two methods have complementary strengths.
doi:10.1371/journal.pcbi.1003087.t003
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reference structure needs to be selected. As is clear from Jackson
et al.’s result for imatinib, the E5% enrichment value can change
by a factor of 2 depending on which reference structure is
chosen.
Finally, in order to evaluate the contribution of the local
structural features over sequence information alone, a ‘‘binding
site sequence’’-based approach was implemented (see Text S3) and
used to predict inhibitor binding for the full 38 inhibitor dataset
Figure 9. Per inhibitor Precision-Recall (PR) curves. The x- and y-axis plot the recall and precision, respectively, both ranging from 0 to 1. The
Area Under Curve (AUCPR) per drug can be found in Table 3. As shown above, CCORPS is demonstrated to have very high precision across a wide
range of inhibitors when tested for targets spanning the kinome.
doi:10.1371/journal.pcbi.1003087.g009
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presented here. The prediction performance for the binding site
sequence-based approach is shown in Table 3 in terms of roc and
pr auc as well as enrichment score. The binding site sequence-
based approach outperformed CCORPS by a significant margin for
several inhibitors: Staurosporine, Sunitinib, SU-14813, PKC-412,
JNJ-7706621, VX-680. These 6 inhibitors on which CCORPS
significantly underperforms are 6 of the top 7 inhibitors in terms
of number of kinases inhibited. That is, the aforementioned 6
inhibitors are relatively promiscuous and tend to interact with a
large number of kinases across several kinase families. Further-
more these same 6 inhibitors also have the 6 highest hpc counts
across the entire dataset. This result indicates that CCORPS has
difficulty predicting inhibitor binding for broad spectrum inhib-
itors and is discussed further in the following section. In the cases
of JNJ-7706621 and VX-680, the performance difference is only
significant in terms of the enrichment score. CCORPS significantly
outperforms the binding site sequence-based approach for several
narrow spectrum inhibitors including, but not limited to:
Lapatinib, CP-724714, CP-690550, SB-431542, VX-745. Overall,
when CCORPS performed better than the sequence-based approach
the magnitude of the performance difference tended to be larger
than when it performed worse. It should also be noted that the
standard deviations of the differences between in AUCROC,
AUCPR, and enrichment score (0.21, 0.33, and 0.36, respectively)
highlight that the two methods have complementary strengths. We
repeated the cross-fold validation using 50% sequence identity
(instead of 70%) to determine the folds. This makes the prediction
problem harder for both CCORPS and the sequence-based approach
(see Table S2). The mean performance is slightly lower for both,
but the standard deviations of the differences in performance
remain the same, reinforcing the observation that CCORPS and the
sequence-based approach have complementary strengths.
Discussion
Identifying structural features of the kinase binding site that
directly or indirectly mediate the binding ability of inhibitors is a
significant component in developing and optimizing kinase
inhibitors. Given the increasingly large number of available kinase
structures, kinome-wide comparative binding site analysis is now
possible as has been demonstrated here. By combining available
structure data with large-scale inhibitor affinity data, it becomes
possible to automatically learn the features of the kinase binding
site that predict the binding ability of a given inhibitor. This is
useful for predicting whether kinases whose binding affinity is
unknown will bind to a given drug, but, perhaps more
importantly, knowing the structural basis for binding to a
particular drug can be exploited in the design of analogs that
bind more strongly and have fewer off-target interactions. This
information could further improve well-established structure-based
computer-aided drug design methods, where it is challenging to
develop reliable models for the contributions of individual
interactions or groups of interactions between inhibitor and
protein to binding affinity.
CCORPS has been demonstrated here to be capable of learning
the features of the kinase binding site that are informative of
inhibitor binding across a set of 38 inhibitors. Furthermore, the
binding site features selected by CCORPS as informative of inhibitor
activity/inactivity have been shown to be interesting in and of
themselves, for example, the existence of residue triad clusters that
are unique in kinases capable of binding a given inhibitor but that
exist within kinases from different major branches of the kinase
family tree. The identification of such shared binding site features
among sequence-diverse kinases is an important contribution for
structure-based methods because of the relative difficulty of
identifying small subsets of sequence non-contiguous but spatially
compact positions that are correlated with a given indicator, such
as inhibitor binding ability. The complete set of 41,964 true-
majority HPCS that contain kinases from two or more of the
kinome families as defined by Manning et al. [2] is provided as
Dataset S1 to facilitate further analysis of these phylogenetically
diverse structural features that distinguish kinases binding each of
the 38 inhibitors.
As was demonstrated here, CCORPS is capable of incorporating
all of the available protein kinase structure data, so as to operate at
the kinome scale, and then using this data to construct highly
accurate predictors of kinase affinity for a variety of different small
molecule inhibitors. While CCORPS relies upon the aggregation of
structural similarity that coincides with affinity similarity to build
predictors, the individual instances may be informative in and of
themselves. Further analysis of the vast number of structurally
similar features shared among phylogenetically distant kinases may
provide additional insights into the structural mechanisms of
inhibitor recognition occurring across the kinome.
The existence of affinity datasets containing structurally similar
inhibitors, that differ by only one or a small number of chemical
substitutions, provides the opportunity to associate specific
structural features identified by CCORPS with specific inhibitor
pharmacophores. A recent approach by Milletti and Hermann [6]
has been demonstrated to identify specific chemical transforma-
tions that can be associated with selectivity differences. In future
work we will seek to further incorporate this cross-inhibitor level of
analysis and broaden the scale of the structure dataset by further
incorporating newly available kinase crystallographic structures.
Several potential optimizations of CCORPS may increase its
inhibitor binding prediction performance on broad spectrum
inhibitors. For the 38 inhibitor dataset analyzed in this paper, the
number of HPCS identified was well correlated with the number of
kinases inhibited (R2~0:69). That is, CCORPS tended to perform
less well on inhibitors for which large numbers of HPCS were
identified. Developing an approach to weighting and ranking the
large number of HPCS generated by broad spectrum inhibitors
may aid in increasing the predictive performance of CCORPS for
these inhibitors. For example, ranking HPCS by the mean within-
cluster affinity (Kd ) would more heavily weight structural features
correlated with strong binders and decrease the impact of
structural features only correlated weak binders. Such an approach
would help to increase the signal-to-noise ratio of HPCS when the
number of HPCS identified grows large. As our results showed,
there are cases where CCORPS significantly outperforms a sequence-
based method, but there also cases where the reverse is true. While
this paper focused on quantifying the extent at which structure
alone can be used to predict binding affinity, for practical usage we
envision that structure- and sequence-based methods are used in
tandem.
A major advantage of the work presented is the generality of
CCORPS to detect structurally distinguishing features for a wide
variety of applications beyond the kinase inhibitor affinity analysis
presented here. No assumptions regarding the nature of the
annotation labels nor of the alignment type are made at any point
by CCORPS. CCORPS provides a general framework for automatically
learning structural features that distinguish proteins having
different annotation labels. This allows the incorporation of purely
structure-based alignments, such as those available in databases
like HOMSTRAD [33] or even local structure alignments such as
those identified by motif/template search algorithms (e.g., SOIPPA
[34], and LabelHash, [35]). Other sources of annotation labels,
including Gene Ontology (GO, [14]) terms, binding affinity for a
Clustering of Residues Predicts Kinome Affinity
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given molecule and ligation state can be incorporated as-is with
CCORPS without modification to the method.
Supporting Information
Figure S1 Structure-based binding site alignment via
MATT. In order to identify a mapping between residues in the TK
and non-TK PFAM alignments, MATT was used to compute a
structural alignment of the kinase domains of p38 structure
PDB:3HEC (white) and LCK structure PDB:2Pl0 (black), both with
bound imatinib inhibitor (red). The Ca rmsd of the above binding
site alignment region (27 residue positions) was 1.169 A˚ and the
RMSD of the imatinib inhibitors is 1.736 A˚; the imatinib molecule
coordinates were ignored during computation of the alignment.
(TIF)
Figure S2 Substructure clustering for one 3-position
subset of the a-amylase binding site alignment. In each
scatter plot above, the dimensionality-reduced feature vectors
computed by CCORPS are shown. Each point shown is one feature
vector and each feature vector represents one protein substructure.
Tightly grouped points correspond to binding site substructures
with high structural and chemical similarity. Plots A, B and C
above all show the same clustering with different sets of annotation
labels applied (labels are denoted by color): (A) cluster ID labeling;
(B) 3-tier EC labeling; (C) 4-tier EC labeling. Solid ellipses
indicated clusters identified automatically as HPCS. Dashed
ellipses indicate subsets of non-HPC clusters that would have been
considered HPCS if the clustering step had distinguished each as a
separate cluster.
(TIF)
Dataset S1 The complete set of 41,964 true-majority
HPCS that contain kinases from two or more of the
kinome families.
(CSV)
Text S1 Details on the mapping and alignment of
positions among structures within the kinase dataset.
(PDF)
Text S2 Using CCORPS to predict the EC classification for
an extensive dataset of 48 families constructed using the
PFAM database: a large-scale validation experiment.
(PDF)
Text S3 Details of the CCORPS method.
(PDF)
Table S1 Accuracy of predicted EC classifications for
Pfam protein families in cross-fold validation. Predictions
are made at all 4 tiers of the EC hierarchy.
(PDF)
Table S2 Affinity prediction performance of CCORPS for
the kinase inhibitors using a 50% sequence identity
clusters for cross validation. For each of the 38 inhibitors in
the affinity dataset of Karaman et al., the prediction performance
of CCORPS and the sequence-based method is shown below. While
the mean auc values and enrichment scores are close, the standard
deviations of the differences between the corresponding columns
(0.21, 0.31, and 0.40, respectively) highlight that the two methods
have complementary strengths.
(PDF)
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